[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Feifei Huang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100643269","construction-and-feasibility-study-of-a-home-based-intelligent-symptom-management-program-for-lung-cancer-patients-receiving-combined-drug-therapy-based-on-symptom-journey-profiling-100643269",false,"NCT07632703","Construction and Feasibility Study of a Home-Based Intelligent Symptom Management Program for Lung Cancer Patients Receiving Combined Drug Therapy Based on Symptom Journey Profiling","Inclusion Criteria:\n\n* Diagnosed with primary lung cancer confirmed by histology or cytology\n* First-time recipient of combination drug therapy, with an expected treatment course of at least 4 cycles; the combination regimen is not restricted\n* Aged 18 years or older\n* Able to use a smartphone\n* Eastern Cooperative Oncology Group performance status score of 2 or lower\n* Aware of their own diagnosis and medication regimen\n* Voluntarily agree to participate in this study\n\nExclusion Criteria:\n\n* History of mental illness or currently receiving mental health treatment\n* Diagnosis of malignancy in another organ site\n* Presence of cognitive impairment, indicated by 3 or more errors on the Short Portable Mental Status Questionnaire","ALL","18 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"NA","The goal of this clinical trial is to develop and evaluate a home-based intelligent symptom management program based on symptom journey profiles for patients with lung cancer receiving combination drug therapy. The program will be delivered through the \"Zhihu Feifang\" WeChat mini-program and is designed to help patients monitor symptoms, receive personalized symptom management recommendations, and obtain timely support during treatment intervals at home.\n\nThe study will assess the feasibility, acceptability, and preliminary effectiveness of this intelligent symptom management program.\n\nThe main research questions are as follows: (1) Is the intelligent symptom management program feasible and acceptable for patients with lung cancer receiving combination drug therapy? (2) Compared with usual care, can the program reduce symptom burden and improve symptom self-management ability? (3) Can the program improve quality of life and help patients identify and manage symptoms more promptly during treatment intervals? Researchers will compare the intelligent symptom management program with usual care to evaluate its preliminary effectiveness. Participants will be randomly assigned to either the intervention group or the usual care group.\n\nParticipants in the intervention group will: (1) Receive usual care plus the \"Zhihu Feifang\" WeChat mini-program intervention; (2) Use the mini-program during four consecutive treatment intervals, lasting approximately 4 months; (3) Complete regular symptom assessments through the mini-program; (4) Receive personalized symptom management education, coping strategies, and risk alerts based on their symptom severity and symptom changes; (5) Receive nurse monitoring and follow-up support when needed; (6) Complete questionnaires at baseline and at follow-up time points during the study; (7) Some participants may also take part in an interview after the intervention to share their experience and suggestions.\n\nParticipants in the usual care group will receive routine follow-up care, including health education, telephone follow-up, and medical visit guidance.",[25,26,27],"Lung Neoplasms","Symptom Management","mHealth Intervention","NOT_YET_RECRUITING","2026-06-02",{"date":31,"type":32},"2026-06-08","ACTUAL",{"date":34,"type":19},"2026-05-25",{"date":36,"type":19},"2027-06-30",{"name":38,"class":39},"Feifei Huang","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":59,"locationsCount":4},"100638969","construction-and-preliminary-evaluation-of-dyadic-acceptance-and-commitment-therapy-for-couples-with-fear-of-lung-cancer-recurrence-100638969","NCT07588347","Construction and Preliminary Evaluation of Dyadic Acceptance and Commitment Therapy for Couples With Fear of Lung Cancer Recurrence","Inclusion Criteria\n\nPatients:\n\n* Diagnosis of primary lung cancer confirmed by pathological examination.\n* Age ≥ 22 years for men and ≥ 20 years for women (legal marriage age in China).\n* Have undergone lung cancer surgery and are scheduled to receive the first round of radiotherapy and\u002For chemotherapy treatment\n* Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) score ≥ 13, indicating moderate-to-severe FCR.\n* Eastern Cooperative Oncology Group (ECOG) ≤2.\n* Aware of their diagnosis and willing to participate voluntarily.\n* Normal cognitive function (Montreal Cognitive Assessment \\[MoCA\\] score ≥ 26), alert and conscious, and able and willing to communicate their thoughts.\n\nSpouse Caregivers:\n\n* Identified by the patient as the primary caregiver, providing ≥ 50% of care in the past 2 weeks.\n* Legally married to the patient.\n* Age ≥ 22 years for men and ≥ 20 years for women.\n* Normal cognitive function (MoCA score ≥ 26), no diagnosed mental disorders, able to communicate effectively, and willing to share their thoughts.\n\nExclusion Criteria\n\nPatients:\n\n* Diagnosed mental disorders or currently receiving psychiatric treatment.\n* Presence of personality disorders, intellectual disability, memory disorders, brain injury, or neurological disease.\n* Concurrent malignant tumors in other organs.\n* Severe complications (e.g., chest pain and\u002For dyspnea due to pleural tumor invasion).\n* Spouse caregiver unwilling to participate.\n* History of upper limb fractures or surgery resulting in impaired hand function.\n* Participation in other similar psychological interventions.\n\nSpouse Caregivers:\n\n* Presence of serious comorbid conditions (e.g., respiratory failure, malignant tumors, or other critical illnesses).\n* Patient unwilling to participate.\n* Participation in other research studies.","20 Years",{"count":48,"type":19},72,[22],"The goal of this clinical trial is to develop a simple, scientific, effective, and culturally adapted dyadic Acceptance and Commitment Therapy (ACT) intervention program (the ADAPT program) targeting fear of cancer recurrence (FCR) among lung cancer patients and their spouse caregivers. The study will also evaluate the feasibility, acceptability, and preliminary effectiveness of the ADAPT program.\n\nThe main research questions are as follows:\n\n* Is the ADAPT intervention program feasible and acceptable for lung cancer patients and their spouse caregivers?\n* Compared with usual care, can the ADAPT intervention program preliminarily reduce FCR levels in both patients and their spouse caregivers? Can the program improve coping styles, illness perceptions, family functioning, and intimate relationships among both patients and their spouse caregivers? Can the program enhance psychological flexibility and quality of life (QOL) in both patients and their spouse caregivers? Researchers will compare the ADAPT intervention program with usual care to evaluate its preliminary effectiveness in reducing FCR among lung cancer patients and their spouse caregivers.\n\nParticipants will:\n\n* Receive the ADAPT intervention twice during each radiotherapy and\u002For chemotherapy cycle, for a total of three treatment cycles (approximately 3 months);\n* Complete questionnaires at baseline (before the intervention), immediately after the intervention, and one month post-intervention;\n* Report outcomes including FCR severity, FCR triggers, psychological flexibility, illness perception, dyadic coping, family functioning, intimacy, and quality of life (QOL).",[25,52,53],"Acceptance and Commitment Therapy","Spouses","2026-05-15",{"date":56,"type":32},"2026-05-19",{"date":54,"type":19},{"date":36,"type":19},{"name":38,"class":39},""]